OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) has had a solid 2017 trading from .25 cents to $2.75 in the first quarter. The share price move was a bit delayed in the way investors recognized the cannabis sector value for this bio-pharma play. But shares have had a few fits and starts, and look below at the chart and the price action tells a story of uncertainty as shares retraces the early move for a re-test of the $1.00 support level.
Traveling through the floor on a number of occasions, we think closes above this $1.00 floor will be critical as we move through subsequent quarters and cannabis matures as a viable investment sector.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that the Scientific Advisory Team of its wholly owned Israeli subsidiary, One World Cannabis Ltd. (“OWC”) has determined the road map for continuing the Multiple Myeloma study.
Subscribe below and we’ll keep you on top of what’s happening before OWCP stock makes its next move.
$OWCP 10-Day Chart Below:
The purpose of the next phase of the study, which is based upon the promising results of the Company’s earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] in order to best determine the most effective dosages and means of delivery for a future the planned study on human patients following receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Dr. Yehuda Baruch, the Company’s Chief Science Officer and Director of Research and Regulatory Affairs of OWC stated “after in-depth and extensive review and assessment of the study’s results accumulated so far, OWC’s research committee determined that the medical and scientific accepted multiple myeloma mice model is the best way to progress, compared to other possible known scientific paths. This unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time may potentially enhance response to various multiple myeloma treatment regimes.
The initial OWC study was conducted at the Israeli-renowned Academic Medical Center (affiliated with Tel-Aviv University) using three repetitive tests on the effect of OWC’s proprietary cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50% concentration).
The results from our earlier study demonstrated more than 60% malignant cell death. In view of the basic study results, OWC has begun the development of a unique formulation that includes cannabis extracts for a new delivery system in the form of a cannabis dissoluble tablet to treat multiple myeloma. The cannabis dissoluble tablet will provide physicians with the ability to control and administrate optimal dosage. This can be treated with every multiple myeloma patient and will replace the common usage of smoking medical cannabis today which is not widely accepted by scientists and physicians as smoking, edibles and oil extracts with no meaningful or substantial dosage control.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) has similar chart patterns to many in the industry (which has become bifurcated)if you compare some of the research driven companies who needed to use shares as currency. The Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
We are watching the important volume indicator for the company as well as an aforementioned close above the $1.00 mark as significant metric to watch for them, stay tuned here for news about our growing sector of cannabis names. For more news on OWC Pharmaceutical Research Corp. and other fast-moving penny stocks, please subscribe to OracleDispatch.com below.